These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 37787009)

  • 21. Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment.
    Grabowski J; Yurdaydìn C; Zachou K; Buggisch P; Hofmann WP; Jaroszewicz J; Schlaphoff V; Manns MP; Cornberg M; Wedemeyer H;
    Liver Int; 2011 Oct; 31(9):1395-405. PubMed ID: 21762356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy.
    Bazinet M; Pântea V; Placinta G; Moscalu I; Cebotarescu V; Cojuhari L; Jimbei P; Iarovoi L; Smesnoi V; Musteata T; Jucov A; Dittmer U; Krawczyk A; Vaillant A
    Gastroenterology; 2020 Jun; 158(8):2180-2194. PubMed ID: 32147484
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiviral treatment and liver-related complications in hepatitis delta.
    Wranke A; Serrano BC; Heidrich B; Kirschner J; Bremer B; Lehmann P; Hardtke S; Deterding K; Port K; Westphal M; Manns MP; Cornberg M; Wedemeyer H
    Hepatology; 2017 Feb; 65(2):414-425. PubMed ID: 27770553
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does interferon-sparing tenofovir disoproxil fumarate-based therapy have a role in the management of severe acute hepatitis delta superinfection?
    Babiker ZOE; Hogan C; Ustianowski A; Wilkins E
    J Med Microbiol; 2012 Dec; 61(Pt 12):1780-1783. PubMed ID: 22956751
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial.
    Wedemeyer H; Schöneweis K; Bogomolov P; Blank A; Voronkova N; Stepanova T; Sagalova O; Chulanov V; Osipenko M; Morozov V; Geyvandova N; Sleptsova S; Bakulin IG; Khaertynova I; Rusanova M; Pathil A; Merle U; Bremer B; Allweiss L; Lempp FA; Port K; Haag M; Schwab M; Zur Wiesch JS; Cornberg M; Haefeli WE; Dandri M; Alexandrov A; Urban S
    Lancet Infect Dis; 2023 Jan; 23(1):117-129. PubMed ID: 36113537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of hepatitis delta virus genotype 3 infection with peg-interferon and entecavir.
    Borzacov LM; de Figueiredo Nicolete LD; Souza LF; Dos Santos AO; Vieira DS; Salcedo JM
    Int J Infect Dis; 2016 May; 46():82-8. PubMed ID: 27005283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome.
    Keskin O; Wedemeyer H; Tüzün A; Zachou K; Deda X; Dalekos GN; Heidrich B; Pehlivan S; Zeuzem S; Yalçın K; Gürel S; Tabak F; Idilman R; Bozkaya H; Manns M; Yurdaydin C
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2342-49.e1-2. PubMed ID: 26044319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beyond Pegylated Interferon-Alpha: New Treatments for Hepatitis Delta.
    Deterding K; Wedemeyer H
    AIDS Rev; 2019; 21(3):126-134. PubMed ID: 31532397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of chronic hepatitis delta virus with peg-interferon and factors that predict sustained viral response.
    Samiullah S; Bikharam D; Nasreen
    World J Gastroenterol; 2012 Oct; 18(40):5793-8. PubMed ID: 23155322
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients.
    Loglio A; Ferenci P; Uceda Renteria SC; Tham CYL; van Bömmel F; Borghi M; Holzmann H; Perbellini R; Trombetta E; Giovanelli S; Greco L; Porretti L; Prati D; Ceriotti F; Lunghi G; Bertoletti A; Lampertico P
    J Hepatol; 2019 Oct; 71(4):834-839. PubMed ID: 31302176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Pegylated Interferon Plus Tenofovir Combination on Higher Hepatitis B Surface Antigen Loss in Treatment-naive Patients With Hepatitis B e Antigen -positive Chronic Hepatitis B: A Real-world Experience.
    Hu C; Song Y; Tang C; Li M; Liu J; Liu J; Liao M; Zhou F; Zhang YY; Zhou Y
    Clin Ther; 2021 Mar; 43(3):572-581.e3. PubMed ID: 33516527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized controlled trial of pegylated interferon-alpha with tenofovir disoproxil fumarate for hepatitis B e antigen-negative chronic hepatitis B: A 48-week follow-up study.
    Bahardoust M; Mokhtare M; Barati M; Bagheri-Hosseinabadi Z; Karimi Behnagh A; Keyvani H; Agah S
    J Infect Chemother; 2020 Dec; 26(12):1265-1271. PubMed ID: 32762882
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prolonged duration of the routine pegylated-interferon alfa-2a therapy produces superior virological response in HBeAg-positive chronic hepatitis B patients: a single-center cohort study].
    Zhu YY; Wu YL; Chen J; Zheng Q; Dong J; Jiang JJ
    Zhonghua Gan Zang Bing Za Zhi; 2012 Oct; 20(10):737-41. PubMed ID: 23207332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B.
    Marcellin P; Ahn SH; Ma X; Caruntu FA; Tak WY; Elkashab M; Chuang WL; Lim SG; Tabak F; Mehta R; Petersen J; Foster GR; Lou L; Martins EB; Dinh P; Lin L; Corsa A; Charuworn P; Subramanian GM; Reiser H; Reesink HW; Fung S; Strasser SI; Trinh H; Buti M; Gaeta GB; Hui AJ; Papatheodoridis G; Flisiak R; Chan HL;
    Gastroenterology; 2016 Jan; 150(1):134-144.e10. PubMed ID: 26453773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
    Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta.
    Sandmann L; Yurdaydin C; Deterding K; Heidrich B; Hardtke S; Lehmann P; Bremer B; Manns MP; Cornberg M; Wedemeyer H; Maasoumy B;
    Hepatol Commun; 2022 Mar; 6(3):480-495. PubMed ID: 34561972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-α2a treatment.
    Mederacke I; Yurdaydin C; Dalekos GN; Bremer B; Erhardt A; Cakaloglu Y; Yalcin K; Gurel S; Zeuzem S; Zachou K; Bozkaya H; Dienes HP; Manns MP; Wedemeyer H;
    Antivir Ther; 2012; 17(2):305-12. PubMed ID: 22293066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Peg-IFNa-2a/RBV antiviral efficacy in cirrhotic hepatitis C patients after splenectomy or partial splenic embolization].
    Xie YM; Li B; Ma L; Pan L; Wei X; Peng XJ; Hao CQ; Zhang Y; Bai XF; Kang WZ; Jia ZS
    Zhonghua Gan Zang Bing Za Zhi; 2012 Feb; 20(2):112-5. PubMed ID: 22464782
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resolution of chronic hepatitis Delta after 1 year of combined therapy with pegylated interferon, tenofovir and emtricitabine.
    Mansour W; Ducancelle A; Le Gal F; Le Guillou-Guillemette H; Abgueguen P; Pivert A; Calès P; Gordien E; Lunel F
    J Clin Virol; 2010 Jan; 47(1):97-9. PubMed ID: 19914127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.